Browse the evidence

Endoscopic hydrothermal duodenal mucosal resurfacing has an acceptable safety profile.

This procedure can be considered for patients with a focus on safety.

Biliopancreatic diversion (BPD) and mini gastric bypass (mini-GBP) have the highest diabetes remission rates among the surgical treatments analyzed.

Clinicians should consider BPD and mini-GBP as effective options for achieving diabetes remission in patients.

Sleeve gastrectomy has emerged as the most popular bariatric procedure in the last 10 years.

Surgeons should be aware that sleeve gastrectomy is currently the preferred option among patients.

BAT thermal activity does not change in response to overfeeding.

Overfeeding does not affect BAT thermal activity in men.

BAT thermal activity does not correlate with the degree of metabolic adaptation.

BAT activity does not influence metabolic adaptation to overfeeding.

Patients who had bariatric surgery for morbid obesity after liver transplantation had a 16% post-bariatric surgery major complication rate.

Caution is advised for patients undergoing bariatric surgery after liver transplantation due to a higher complication rate.

The need for more effective treatments for obesity is obvious due to the far-reaching effects of the condition.

Healthcare providers should prioritize finding effective obesity treatments.

30% of steep losers died during postintervention follow-up versus 10-18% in other trajectories.

Monitoring for excessive weight loss is crucial, especially in older adults with diabetes.

There is no clear evidence that GLP-1RAs and dual GLP-1/GIPRA enhance cardiorespiratory fitness (CRF).

Practitioners should be cautious in expecting improvements in CRF from these therapies.

The long-acting PYY analogs improved glucose metabolism in diabetic db/db mice.

Indicates potential for improved glucose control in diabetic patients.

Individuals with Friedreich's ataxia (FRDA) have lower insulin sensitivity (whole-body insulin sensitivity index 2.8 vs 5.3, P < .01) compared to controls.

Practitioners should be aware that FRDA is associated with reduced insulin sensitivity, which may impact metabolic health.

Obesity is a chronic metabolic disorder that shares underlying pathophysiology with type 2 diabetes mellitus, cardiovascular disease, and diabetic cardiomyopathy.

Understanding the metabolic links can help in developing targeted interventions for obesity and related diseases.

Glucose is essential for the functioning of the pentose phosphate pathway (PPP) and cannot be substituted by other metabolites.

Practitioners should recognize the critical role of glucose in metabolic processes.

Prior GLP-1 agonist use is not associated with in-hospital mortality in critically ill patients.

Clinicians may consider that prior GLP-1 agonist use does not adversely affect mortality in critically ill patients.

Prior GLP-1 agonist use is not associated with hospital length of stay in critically ill patients.

Clinicians may conclude that prior GLP-1 agonist use does not prolong hospital stays for critically ill patients.

Prior GLP-1 agonist use is not associated with ICU length of stay in critically ill patients.

Clinicians may determine that prior GLP-1 agonist use does not affect ICU length of stay for critically ill patients.

Liraglutide did not have measurable effects on lean or bone tissue over the 18-day period.

Liraglutide may not affect muscle or bone mass in the short term.

SGLT-2 inhibitors lower blood sugar independently of insulin, reduce heart failure risk, slow kidney disease progression, and possess senolytic properties.

SGLT-2 inhibitors may be beneficial for patients with diabetes and related complications.

Substantial investments in coordinated nutrition and agricultural research are needed to transform the food system.

This highlights the importance of policy and research in addressing obesity and food security.

GC ablation in mice fed a high fat diet protects against obesity and type 2 diabetes.

This suggests that targeting GC could be beneficial in preventing obesity in high-fat diet scenarios.

Adjustment for covariates differing between trial type and associated with BW reduction nullified the association between T2D status and weight loss (p = 0.93).

This suggests that addressing demographic and comorbid factors may improve weight loss outcomes in T2D patients.

No significant differences in metabolic flexibility were observed between the RE+CON and RE+PRO groups.

Combining resistance exercise with either a control or high protein diet does not significantly alter metabolic flexibility outcomes.

Polypharmacy is more common in women with diabetes than in men with diabetes.

Healthcare providers should be aware of the higher likelihood of polypharmacy in female diabetes patients.

CE/BZA treatment produced no detectable effect on insulin sensitivity, body composition, ectopic fat, fat cell size, or substrate oxidation.

CE/BZA does not improve insulin sensitivity or body composition in this population.